Report Sections

See All Reports

  • HP:0002894: Neoplasm of the pancreas
  • Pneumonia (359) Respiratory tract infection (38) Neoplasm (36) Abnormality of the cardiovascular system (34) Diabetes mellitus (33) Depressivity (29) Acute kidney injury (27) Hypoxemia (26) Hypertension (24) Abnormal lung morphology (24) Thromboembolism (22) Anosmia (20) Myocardial infarction (20) Arthritis (19) Type II diabetes mellitus (18) Stroke (16) Pulmonary embolism (16) Mental deterioration (15) Abnormality of coagulation (15) Pulmonary fibrosis (15) Chronic pulmonary obstruction (15) Abnormality of the kidney (14) Autistic behavior (14) Rheumatoid arthritis (14) Leukemia (14) Interstitial pneumonitis (14) Pulmonary obstruction (14) Asthma (13) Chronic pain (13) Congestive heart failure (12) Deep venous thrombosis (12) Neoplasm of the lung (12) Autism (11) Obesity (11) Respiratory distress (11) Colitis (11) Ulcerative colitis (11) Crohn's disease (11) Type I diabetes mellitus (10) Abnormality of the liver (9) Coronary artery atherosclerosis (9) Inflammation of the large intestine (9) Pulmonary insufficiency (9) Chronic kidney disease (9) Myocarditis (9) Behavioral abnormality (8) Psychosis (8) Dementia (8) Alzheimer disease (8) Carcinoma (8) Low levels of vitamin D (8) Sepsis (8) Infertility (7) Peripheral arterial stenosis (7) Renal insufficiency (6) Lymphopenia (6) Dysphagia (6) Lymphoma (6) Systemic lupus erythematosus (6) Osteoarthritis (6) Breast carcinoma (6) Psoriasiform dermatitis (6) Abnormality of the gastrointestinal tract (6) Fatigue (6) Encephalopathy (5) Premature birth (5) Bronchiectasis (5) Difficulty walking (5) Gastroparesis (5) Immunodeficiency (5) Obstructive sleep apnea (5) Autoimmunity (5) Knee osteoarthritis (5) Sleep apnea (5) Prostate cancer (5) Allergy (5) Non-small cell lung carcinoma (5) Schizophrenia (5) Neoplasm of the large intestine (5) Seizure (4) Hepatic fibrosis (4) Cardiac arrest (4) Weight loss (4) Migraine (4) Pulmonary arterial hypertension (4) Abnormal intestine morphology (4) Neoplasm of the pancreas (4) Colon cancer (4) Malnutrition (4) Paroxysmal atrial fibrillation (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Inflammatory abnormality of the skin (4) Neoplasm of head and neck (4) Endometriosis (4) Addictive behavior (4) Hypercoagulability (4) Insomnia (4) Obsessive-compulsive behavior (3) Eczema (3) Atopic dermatitis (3) Spastic diplegia (3) Abnormal heart morphology (3) Cardiomyopathy (3) Fever (3) Hypothermia (3) Headache (3) Celiac disease (3) Reduced factor VIII activity (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Abnormal anterior horn cell morphology (3) Amyotrophic lateral sclerosis (3) Cystoid macular edema (3) Arrhythmia (3) Cutaneous melanoma (3) Pulmonary edema (3) Ovarian neoplasm (3) Neuroendocrine neoplasm (3) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Cataract (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormality of the skin (2) Jaundice (2) Lymphedema (2) Spasticity (2) Meningitis (2) Abnormal joint morphology (2) Hepatic steatosis (2) Hepatic failure (2) Tachycardia (2) Angina pectoris (2) Pancreatitis (2) Abnormality of blood and blood-forming tissues (2) Thrombocytopenia (2) Autoimmune thrombocytopenia (2) Gout (2) Diarrhea (2) Gastroesophageal reflux (2) Apnea (2) Neurodegeneration (2) Alopecia of scalp (2) Mutism (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Hypotension (2) Atherosclerosis (2) Hypoventilation (2) Squamous cell carcinoma (2) Myelodysplasia (2) Back pain (2) Low back pain (2) Muscular dystrophy (2) Stillbirth (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Postprandial hyperglycemia (2) Hemeralopia (2) Arteritis (2) Hepatitis (2) Glioblastoma multiforme (2) Cervix cancer (2) Small cell lung carcinoma (2) Endocarditis (2) Toxemia of pregnancy (2) Myositis (2) Mania (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Otitis media (1) Conductive hearing impairment (1) Amblyopia (1) Periodontitis (1) IgA deposition in the glomerulus (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Urticaria (1) Angiokeratoma corporis diffusum (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Cerebral hemorrhage (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Premature rupture of membranes (1) Dehydration (1) Constipation (1) Anorexia (1) Esophageal varix (1) Chorea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Abnormality of the spinal cord (1) Memory impairment (1) Encephalitis (1) Spina bifida (1) Language impairment (1) Waddling gait (1) Increased intracranial pressure (1) Biliary cirrhosis (1) Dilatation (1) Osteomyelitis (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Bruxism (1) Neonatal death (1) Increased body weight (1) Intermittent claudication (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Acute myelomonocytic leukemia (1) Dilatation of the cerebral artery (1) Coronary artery stenosis (1) Venous insufficiency (1) Chronic lymphatic leukemia (1) Abnormality of bone marrow cell morphology (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Bladder neoplasm (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Placental abruption (1) Sinus tachycardia (1) Bronchiolitis (1) Erythroid hypoplasia (1) Asterixis (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Heart block (1) Cough (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Abnormality of movement (1) Subdural hemorrhage (1) Biliary tract neoplasm (1) Nasal polyposis (1) Eclampsia (1) Esophagitis (1) Vaginal neoplasm (1) Cellulitis (1) Angioedema (1) Self-injurious behavior (1) Gastrointestinal stroma tumor (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0002894: Neoplasm of the pancreas

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (11)


    Name (Synonyms) Correlation
    drug103 ADCT-301 Wiki 0.50
    drug2286 Maraviroc+Favipiravir+CT Wiki 0.50
    drug1024 Continuation of ACEi/ARB Wiki 0.50
    Name (Synonyms) Correlation
    drug1112 Curently used therapy for COVID-19 non-critical patients Wiki 0.50
    drug1516 Favipiravir + Currently used therapy Wiki 0.50
    drug2809 Palliative care assessment Wiki 0.50
    drug1384 Endoscopic management according to standard of care Wiki 0.50
    drug1241 Discontinuation of ACEi/ARB Wiki 0.50
    drug1429 Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancer Wiki 0.50
    drug2284 Maraviroc + Currently used therapy Wiki 0.50
    drug2852 Pembrolizumab Wiki 0.35

    Correlated MeSH Terms (9)


    Name (Synonyms) Correlation
    D010190 Pancreatic Neoplasms NIH 1.00
    D002761 Cholangitis NIH 0.50
    D018281 Cholangiocarcinoma NIH 0.50
    Name (Synonyms) Correlation
    D008105 Liver Cirrhosis, Biliary NIH 0.50
    D041781 Jaundice, Obstructive NIH 0.50
    D007565 Jaundice, NIH 0.35
    D002292 Carcinoma, Renal Cell NIH 0.29
    D064726 Triple Negative Breast Neoplasms NIH 0.22
    D002277 Carcinoma NIH 0.18

    Correlated HPO Terms (6)


    Name (Synonyms) Correlation
    HP:0030153 Cholangiocarcinoma HPO 0.50
    HP:0002613 Biliary cirrhosis HPO 0.50
    HP:0030151 Cholangitis HPO 0.50
    Name (Synonyms) Correlation
    HP:0000952 Jaundice HPO 0.35
    HP:0005584 Renal cell carcinoma HPO 0.29
    HP:0030731 Carcinoma HPO 0.18

    Clinical Trials

    Navigate: Correlations   HPO

    There are 4 clinical trials


    1 A Phase 1b, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) as Monotherapy or in Combination in Patients With Selected Advanced Solid Tumors

    This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment discontinuation.

    NCT03621982
    Conditions
    1. Advanced Solid Tumors With Literature Evidence of CD25(+) Treg Content
    2. Head and Neck Cancer Squamous Cell Carcinoma
    3. Non-small Cell Lung Cancer
    4. Gastric Cancer
    5. Esophageal Cancer
    6. Pancreas Cancer
    7. Bladder Cancer
    8. Renal Cell Carcinoma
    9. Melanoma
    10. Triple-negative Breast Cancer
    11. Ovarian Cancer
    12. Colo-rectal Cancer
    Interventions
    1. Drug: ADCT-301
    2. Biological: Pembrolizumab
    MeSH:Carcinoma Carcinoma, Renal Cell Triple Negative Breast Neoplasms Pancreatic Neoplasms
    HPO:Carcinoma Clear cell renal cell carcinoma Neoplasm of the pancreas Papillary renal cell carcinoma Renal cell carcinoma

    Primary Outcomes

    Description: An AE is defined as any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product, which does not necessarily have to have a causal relationship with this treatment.

    Measure: Assessment of Dose Limiting Toxicities in Determination of the Maximum Tolerated Dose Limiting toxicities as defined per protocol, as related to ADCT-301

    Time: Up to 3 years

    Description: Adverse events will be graded according to CTAE v4.0 (or more recent). For events not included in the CTCAE criteria, the severity of the AE will be graded on a scale of 1 to 5.

    Measure: Number of Adverse Events of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or Above

    Time: Up to 3 years

    Description: A SAE is defined as any AE that results in death, is life threatening, requires inpatient hospitalization of prolongation of existing hospitalization (hospitalization for elective procedures or for protocol compliance is not considered an SAE), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or important medical events that do not meet the preceding criteria but based on appropriate medical judgement may jeopardize the patient or may require medical or surgical intervention to prevent any of the outcomes listed above.

    Measure: Number of Serious Adverse Events (SAE)

    Time: Up to 3 years

    Description: AEs will be graded according to CTCAE v.4.0 (or more recent). For events not included in the CTCAE criteria, the severity of the AE will be graded on a scale of 1 to 5.

    Measure: Number of SAEs of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or Above

    Time: Up to 3 years

    Measure: Number of Dose Interruptions and/or Dose Reductions

    Time: Up to 3 years

    Measure: Number of Dose Limiting Toxicities

    Time: Up to 3 years

    Measure: Number of Participants who Experience a Clinically Significant Change in Baseline in Laboratory Values

    Time: Up to 3 years

    Measure: Number of Participants who Experience a Clinically Significant Change in Baseline in Vital Signs

    Time: Up to 3 years

    Measure: Number of Participants who Experience a Clinically Significant Change in Baseline in Electrocardiogram (ECG) Results

    Time: Up to 3 years

    Measure: Number of Particpants who Experience a Clinically Significant Change in Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status

    Time: Up to 3 years

    Secondary Outcomes

    Description: Overall response rate (ORR) according to the Response Evaluation Criteria In Solid Tumors (RECIST) v1.1

    Measure: Evaluate the preliminary anti-tumor activity of camidanlumab tesirine

    Time: Up to 3 years

    Description: Duration of response (DOR) defined as the time from the first documentation of tumor response to disease progression as per RECIST v1.1

    Measure: Evaluate the preliminary anti-tumor activity of camidanlumab tesirine

    Time: Up to 3 years

    Description: Progression-free survival (PFS) defined as the time between start of treatment and the first documentation of recurrence or progression as per RECIST v1.1

    Measure: Evaluate the preliminary anti-tumor activity of camidanlumab tesirine

    Time: Up to 3 years

    Description: Overall survival (OS) defined as the time between the start of treatment and death from any cause

    Measure: Evaluate the preliminary anti-tumor activity of camidanlumab tesirine

    Time: Up to 3 years

    Description: Noncompartmental analysis of the maximum concentration (Cmax)

    Measure: Pharmacokinetics and Pharmacodynamics assessment- camidanlumab tesirine total antibody, PBD-conjugated antibody, and unconjugated warhead SG3199 in serum

    Time: Up to 3 years

    Description: Noncompartmental analysis of the time to maximum concentration (Tmax)

    Measure: Pharmacokinetics and Pharmacodynamics assessment- camidanlumab tesirine in serum

    Time: Up to 3 years

    Description: Noncompartmental analysis of the area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0 last)

    Measure: Pharmacokinetics and Pharmacodynamics assessment- camidanlumab tesirine in serum

    Time: Up to 3 years

    Description: Noncompartmental analysis of the area under the concentration-time curve from time zero to infinity (AUC0-∞)

    Measure: Pharmacokinetics and Pharmacodynamics assessment- camidanlumab tesirine in serum

    Time: Up to 3 years

    Description: Noncompartmental analysis of the area under the concentration-time curve from time zero to the end of the dosing interval (AUC0-τ)

    Measure: Pharmacokinetics and Pharmacodynamics assessment- camidanlumab tesirine in serum

    Time: Up to 3 years

    Description: Noncompartmental analysis of the accumulation index (AI)

    Measure: Pharmacokinetics and Pharmacodynamics assessment- camidanlumab tesirine in serum

    Time: Up to 3 years

    Description: Noncompartmental analysis of clearance (CL)

    Measure: Pharmacokinetics and Pharmacodynamics assessment- camidanlumab tesirine in serum

    Time: Up to 3 years

    Description: Noncompartmental analysis of volume of distribution (Vd)

    Measure: Pharmacokinetics and Pharmacodynamics assessment- camidanlumab tesirine in serum

    Time: Up to 3 years

    Description: ADA titers if applicable, neutralizing activity to camidanlumab tesirine after treatment with camidanlumab tesirine.

    Measure: Number of confirmed positive anti-drug antibody (ADA) responses

    Time: Up to 3 years
    2 The Impact of Early Palliative Care on the Quality of Life of Patients With Advanced Pancreas Cancer: A Case-crossover Study

    The primary objective is to explore the impact of early palliative care on quality of life in patients with advanced pancreatic cancer. The secondary objectives are to explore the impact of early palliative care on symptom management, depression, anxiety and survival in patients with advanced pancreatic cancer.

    NCT03837132
    Conditions
    1. Advanced Cancer
    Interventions
    1. Behavioral: Palliative care assessment
    MeSH:Pancreatic Neoplasms
    HPO:Neoplasm of the pancreas

    Primary Outcomes

    Description: For the primary endpoint, we will use a generalized linear model to test for a statistically significant change score between baseline and 16 weeks. We will assume a normal distribution for the change scores. Model fit will be assessed via a visual assessment of residuals and the ratio of the model deviance to its degrees of freedom.

    Measure: Impact of early palliative care on quality of life in patients with advanced pancreatic cancer

    Time: registration to 16 weeks

    Secondary Outcomes

    Description: Secondary endpoints will include: (1) symptom control at 16 weeks as measured by the revised Edmonton Symptom Assessment Scale (ESAS-r) (a widely used and validated tool to assess symptom intensity, which is routinely completed by patients at all CCMB visits); (2) depression and anxiety at 16 weeks using the Hospital Anxiety and Depression Scale (HADS) (a 14 item scale which can be used in the outpatient setting to screen for anxiety and depression within the previous week) and the Patient Health Questionnaire (PHQ-9) (a sensitive (88%) and specific (88%) 9 question tool which incorporates diagnostic criteria for major depression); and overall survival measured from date of registration to death

    Measure: To explore the impact of early palliative care on symptom management, depression, anxiety and survival in patients with advanced pancreatic cancer

    Time: registration to 16 weeks
    3 Effects of Covid-19 Pandemic on Pancreatic Surgery in Italy. A Multicenter Observational Clinical Study

    Pancreatic cancer (PC) is recognized as one of the most challenging tumors to deal with and it is still characterized by a poor long-term prognosis. However, treatment of PC in high-volume centers with the support of a multidisciplinary approach has widely demonstrated improvement both in terms of short- and long-term outcomes. The recent worldwide spread of Covid-19 pandemic significantly affected the healthcare systems of most countries in the world, particularly in red areas such as Italy, with more than 100.000 cases in a two-month time lapse. This inevitably reflected in a reorganization of hospital activities, including the diagnostic and therapeutic pathways for PC treatment. With the aim of giving an objective and real representation of the impact of Covid-19 on PC treatment, the investigator here propose a multicenter Italian observational study comparing a 6-month period before and during the Covid-19 pandemic. Only high-volume centers will be involved in the study. A comparison between the general, clinical, endoscopic and surgical outcomes will be performed by means of a global and month-by-month analysis between the two study periods.

    NCT04380766
    Conditions
    1. Pancreatic Cancer
    Interventions
    1. Procedure: Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancer
    MeSH:Pancreatic Neoplasms
    HPO:Neoplasm of the pancreas

    Primary Outcomes

    Measure: Changes in pancreatic cancer management during the COVID-19 pandemic

    Time: From admission to discharge/last outpatient visit, whichever comes first, assessed up to the 30th of June 2020
    4 The Status of Advanced Endoscopy in the Era of COVID-19: a Multicenter Study

    In this study, investigators aim to explore the status of advanced endoscopy in different endoscopy units all over the world.

    NCT04385147
    Conditions
    1. Cholangitis, Secondary Biliary
    2. Cholangiocarcinoma
    3. Obstructive Jaundice
    4. Pancreas Cancer
    5. COVID-19
    6. SARS-CoV-2
    Interventions
    1. Other: Endoscopic management according to standard of care
    MeSH:Cholangiocarcinoma Pancreatic Neoplasms Cholangitis Liver Cirrhosis, Biliary Jaundice Jaundice, Obstructive
    HPO:Biliary cirrhosis Cholangiocarcinoma Cholangitis Jaundice Neoplasm of the pancreas

    Primary Outcomes

    Description: Investigators will report the baseline demographic data (age, gender, nationality) of all patients.

    Measure: Age, gender, nationality

    Time: 3 months

    Description: Investigators will report the baseline data clinical data (indication for procedure, status of SARS-CoV-2 infection) of all patients.

    Measure: Indication for procedure, status of SARS-CoV-2 infection

    Time: 3 months

    Description: Investigators will report the baseline laboratory data (complete blood count and liver functions tests) of all patients.

    Measure: Complete blood count and liver functions tests

    Time: 3 months

    Description: Investigators will report the procedure related complications.

    Measure: procedure related complications

    Time: 3 months

    Secondary Outcomes

    Description: Investigators will report wether the precautions lead to increase timing of the procedure

    Measure: Effect of COVID-19 precautions on procedure time

    Time: 3 months

    Description: Investigators will report wether the precautions affected staff number (increased or decreased)

    Measure: Effect of COVID-19 precautions on staff number

    Time: 3 months

    HPO Nodes


    Reports

    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,180 reports on interventions/drugs

    MeSH

    691 reports on MeSH terms

    HPO

    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook